Bourlière, Marc <br/><br/>
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.  [electronic resource] 

 -  The lancet. Gastroenterology & hepatology  03 2017 
 - 177-188 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2468-1253 
<br/><br/><label>Standard No.: </label>10.1016/S2468-1253(16)30189-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antiviral Agents--adverse effects<br/>DNA, Viral--blood<br/>Drug Administration Schedule<br/>Female<br/>Hepatitis B Surface Antigens--blood<br/>Hepatitis B e Antigens--blood<br/>Hepatitis B virus--genetics<br/>Hepatitis B, Chronic--blood<br/>Humans<br/>Interferon-alpha--adverse effects<br/>Male<br/>Middle Aged<br/>Nucleosides--adverse effects<br/>Nucleotides--adverse effects<br/>Patient Reported Outcome Measures<br/>Polyethylene Glycols--adverse effects<br/>Recombinant Proteins--adverse effects<br/>Young Adult